About Roxro Pharma
Roxro Pharma is a company based in Menlo Park (United States) founded in 1999 was acquired by Luitpold in December 2010. Roxro Pharma has raised $42.7 million across 1 funding round from investors including Thomas Weisel Partners, Luitpold and Prospect Venture Partners. Roxro Pharma operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Roxro Pharma Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$42.7 M (USD)
in 1 rounds
-
Latest Funding Round
$42.7 M (USD), Series B
Jun 12, 2007
-
Investors
Thomas Weisel Partners
& 3 more
-
Employee Count
Not available
-
Acquired by
Luitpold
(Dec 13, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Roxro Pharma
Roxro Pharma has successfully raised a total of $42.7M through 1 strategic funding round. The most recent funding activity was a Series B round of $42.7 million completed in June 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Roxro Pharma
Roxro Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Thomas Weisel Partners, Luitpold and Prospect Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and healthtech firms.
|
Locked | Locked | Locked | |
|
VC firm investing in the US
|
Locked | Locked | Locked | |
|
Wealth management services are provided to high-net-worth clients.
|
Locked | Locked | Locked |
Investor details for Roxro Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Roxro Pharma
Investment portfolio details for Roxro Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Roxro Pharma
Detailed financials for Roxro Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Roxro Pharma Comparisons
Peer comparison for Roxro Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Roxro Pharma
Roxro Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
Detailed competitors of Roxro Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Roxro Pharma
Complete news archive for Roxro Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Roxro Pharma
Roxro Pharma was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Roxro Pharma is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Roxro Pharma is a funded company, having raised a total of $42.7M across 1 funding round to date.
Roxro Pharma develops drugs for pain treatment. The company acquires discarded or failed drugs from other companies and pushes them through clinical development. Roxro obtained FDA approval for SPRIX Nasal Spray, an intranasal formulation for the treatment of dental and postoperative pain. Other products include: ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine. The company was acquired by Luitpold Pharmaceuticals, a USA-based subsidiary of Japanese drug major Daiichi Sankyo.
Roxro Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Roxro Pharma has 4 investors. Key investors include Thomas Weisel Partners, Luitpold, Prospect Venture Partners, and Sutter Hill Ventures.